Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10286150" target="_blank" >RIV/00216208:11110/14:10286150 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/14:33150530 RIV/00064165:_____/14:10286150
Result on the web
<a href="http://dx.doi.org/10.1038/bjc.2014.504" target="_blank" >http://dx.doi.org/10.1038/bjc.2014.504</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/bjc.2014.504" target="_blank" >10.1038/bjc.2014.504</a>

Result language
angličtina
Original language name
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
Original language description
Background: The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriatelytreated with one or other regimen. Methods: Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10mgkg(-1) days 1 and 15 plus paclitaxel 90 mg m(-2) days 1, 8 and15 q4w) or BEV-CAP (bevacizumab 15 mg kg(-1) day 1 plus capecitabine 1000 mg m(-2) bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)